Literature DB >> 3337861

The dexamethasone suppression test and plasma dexamethasone in generalized anxiety disorder.

J W Tiller1, N Biddle, K P Maguire, B M Davies.   

Abstract

A Dexamethasone Suppression Test nonsuppression rate of 27% was found in a group of 30 generalized anxiety disorder patients before treatment. The dexamethasone concentrations in the eight nonsuppressors were significantly lower than in eight suppressors matched by sex and age, but were similar to those in five nonsuppressors from a matched normal control group. The dexamethasone concentrations in the generalized anxiety disorder suppressors and a matched group of eight normal control suppressors were similar. After successful nondrug behavioral treatment, all generalized anxiety disorder patients were suppressors. Posttreatment dexamethasone concentrations in the initial nonsuppressor patients remained significantly lower than in the initial suppressors. The results suggest that low plasma dexamethasone concentrations after 1 mg oral dexamethasone may confer a vulnerability to nonsuppression that may be expressed in the presence of high state anxiety.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3337861     DOI: 10.1016/0006-3223(88)90037-6

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  7 in total

1.  Effect of Jin-3-needling therapy on plasma corticosteroid, adrenocorticotrophic hormone and platelet 5-HT levels in patients with generalized anxiety disorder.

Authors:  Qing Yuan; Jia-ni Li; Bin Liu; Zhi-feng Wu; Rui Jin
Journal:  Chin J Integr Med       Date:  2007-12       Impact factor: 1.978

Review 2.  Childhood stressful events, HPA axis and anxiety disorders.

Authors:  Carlo Faravelli; Carolina Lo Sauro; Lucia Godini; Lorenzo Lelli; Laura Benni; Francesco Pietrini; Lisa Lazzeretti; Gabriela Alina Talamba; Giulia Fioravanti; Valdo Ricca
Journal:  World J Psychiatry       Date:  2012-02-22

Review 3.  Biological markers for anxiety disorders, OCD and PTSD: A consensus statement. Part II: Neurochemistry, neurophysiology and neurocognition.

Authors:  Borwin Bandelow; David Baldwin; Marianna Abelli; Blanca Bolea-Alamanac; Michel Bourin; Samuel R Chamberlain; Eduardo Cinosi; Simon Davies; Katharina Domschke; Naomi Fineberg; Edna Grünblatt; Marek Jarema; Yong-Ku Kim; Eduard Maron; Vasileios Masdrakis; Olya Mikova; David Nutt; Stefano Pallanti; Stefano Pini; Andreas Ströhle; Florence Thibaut; Matilde M Vaghi; Eunsoo Won; Dirk Wedekind; Adam Wichniak; Jade Woolley; Peter Zwanzger; Peter Riederer
Journal:  World J Biol Psychiatry       Date:  2016-07-15       Impact factor: 4.132

4.  Generalized anxiety and C-reactive protein levels: a prospective, longitudinal analysis.

Authors:  W E Copeland; L Shanahan; C Worthman; A Angold; E J Costello
Journal:  Psychol Med       Date:  2012-04-30       Impact factor: 7.723

5.  Salivary cortisol is associated with diagnosis and severity of late-life generalized anxiety disorder.

Authors:  Rose C Mantella; Meryl A Butters; Janet A Amico; Sati Mazumdar; Bruce L Rollman; Amy E Begley; Charles F Reynolds; Eric J Lenze
Journal:  Psychoneuroendocrinology       Date:  2008-04-14       Impact factor: 4.905

6.  Does the dexamethasone suppression test reliably discriminate between psychotic and nonpsychotic major depression?: an exploratory analysis of potential confounds.

Authors:  Brandon A Gaudiano; Gary Epstein-Lubow; Ivan W Miller
Journal:  J Nerv Ment Dis       Date:  2009-06       Impact factor: 2.254

7.  Homocysteine, cortisol, diabetes mellitus, and psychopathology.

Authors:  K Kontoangelos; C C Papageorgiou; A E Raptis; P Tsiotra; V Lambadiari; G N Papadimitriou; A D Rabavilas; G Dimitriadis; S A Raptis
Journal:  J Diabetes Res       Date:  2015-02-01       Impact factor: 4.011

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.